Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer

Relevance. Breast cancer (BC) is among the most common cancers and the leading causes of cancer death in women worldwide. Much attention is paid to the problem of its hormoneresistance; however, the issues of using prognostic markers and predictors in routine cancer clinical practice remain unresolv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalia I. Samaneva, Liubov I. Vladimirova, Irina V. Kolyadina, Elena M. Frantsiyants, Anna E. Storozhakova, Valeriya A. Bandovkina, Elena A. Kalabanova, Sergei N. Kabanov, Iana V. Svetitskaya, Anna V. Tishina, Mariia O. Ezhova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	breast cancer chemotherapy overall survival hormoneresistance sex hormones cortisol Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a9fdf814b2364cbe9492945661d48d9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a9fdf814b2364cbe9492945661d48d9f
record_format	dspace
spelling	oai:doaj.org-article:a9fdf814b2364cbe9492945661d48d9f2021-11-30T16:55:00ZPrognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer1815-14341815-144210.26442/18151434.2021.1.200716https://doaj.org/article/a9fdf814b2364cbe9492945661d48d9f2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70337/51271https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. Breast cancer (BC) is among the most common cancers and the leading causes of cancer death in women worldwide. Much attention is paid to the problem of its hormoneresistance; however, the issues of using prognostic markers and predictors in routine cancer clinical practice remain unresolved. Aim. Study and analysis of prognostic significance of clinical and biological factors and parameters of the hormonal profile in patients with primary inoperable HER2-negative breast cancer receiving neoadjuvant chemotherapy. Materials and methods. The study included 162 patients with locally advanced primary inoperable HER2-negative breast cancer. Patients were divided into 2 groups. Group 1 included 58 patients with early disease progression within 6 to 12 months after radical surgical treatment. Group 2 included 104 patients with no disease progression within 2 years after radical surgical treatment. In all cases, diagnosis was verified histologically and immunohistochemically. Levels of prolactine, progesterone, estradiol, luteinizing hormone (LH), follicle-stimulating hormone, testosterone and cortisol were measured by RIA. The blood plasma values in 20 healthy donors were used as reference one. The data were processed using the Statistica 7.0 and MedCalc (version 9.3.5.0) programs. All patients received combination antitumor treatment according to clinical guidance. Results. An analysis of the overall (OS) and event-free (EFS) survival in group 1 showed that the median EFS in patients with luminal B BC was 9 months, with triple-negative BC (TNBC) 8 months. 6-month EFS in luminal B subtype was 87.5%, in TNBC 79.4%, p=0.37985. 1-year EFS was 1.721.7% regardless of the biological subtype. The median OS in luminal B BC was 25 months, in TNBC 26 months. 1-year OS in luminal B BC 100%, in TNBC 93.9%, p=0.138. 2-year OS in luminal B BC 54.2%, in TNBC 55.9%, p=0.697. 3-year survival in luminal B BC 37.5%, in TNBC 41.2%, p=0.639. An analysis of OS and EFS in group 2 showed that the median EFS was not reached for all biological subtypes. 3-year survival in the group was 100% regardless of the biological subtype. The median OS was not reached for all biological subtypes. 3-year OS in the group was 100%. An analysis of the hormonal profile in the treatment dynamics showed decreased levels of estradiol in all groups of patients (by 1.6 times). In group 1, progesterone was decreased by 2.1 times, testosterone by 2.4 times and LH by 2.1 times in all BC subtypes (p0.05). Patients of group 2 showed 2 times reduced cortisol and 3 times reduced prolactin in all BC subtypes, while LH levels were elevated by 1.6 times in luminal A and B BC. Conclusion. Aggressive course was observed similarly in triple-negative cancer as well as in luminal cancer with primary hormone resistance. Studying of pituitary and sex hormones and cortisol have a great clinical significance in patients with all biological subtypes of BC. This should be taken into account when predicting the course of the disease and developing further treatment options.Natalia I. SamanevaLiubov I. VladimirovaIrina V. KolyadinaElena M. FrantsiyantsAnna E. StorozhakovaValeriya A. BandovkinaElena A. KalabanovaSergei N. KabanovIana V. SvetitskayaAnna V. TishinaMariia O. EzhovaIP Habib O.N.articlebreast cancerchemotherapyoverall survivalhormoneresistancesex hormonescortisolNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 82-87 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	breast cancer chemotherapy overall survival hormoneresistance sex hormones cortisol Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer chemotherapy overall survival hormoneresistance sex hormones cortisol Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Natalia I. Samaneva Liubov I. Vladimirova Irina V. Kolyadina Elena M. Frantsiyants Anna E. Storozhakova Valeriya A. Bandovkina Elena A. Kalabanova Sergei N. Kabanov Iana V. Svetitskaya Anna V. Tishina Mariia O. Ezhova Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
description	Relevance. Breast cancer (BC) is among the most common cancers and the leading causes of cancer death in women worldwide. Much attention is paid to the problem of its hormoneresistance; however, the issues of using prognostic markers and predictors in routine cancer clinical practice remain unresolved. Aim. Study and analysis of prognostic significance of clinical and biological factors and parameters of the hormonal profile in patients with primary inoperable HER2-negative breast cancer receiving neoadjuvant chemotherapy. Materials and methods. The study included 162 patients with locally advanced primary inoperable HER2-negative breast cancer. Patients were divided into 2 groups. Group 1 included 58 patients with early disease progression within 6 to 12 months after radical surgical treatment. Group 2 included 104 patients with no disease progression within 2 years after radical surgical treatment. In all cases, diagnosis was verified histologically and immunohistochemically. Levels of prolactine, progesterone, estradiol, luteinizing hormone (LH), follicle-stimulating hormone, testosterone and cortisol were measured by RIA. The blood plasma values in 20 healthy donors were used as reference one. The data were processed using the Statistica 7.0 and MedCalc (version 9.3.5.0) programs. All patients received combination antitumor treatment according to clinical guidance. Results. An analysis of the overall (OS) and event-free (EFS) survival in group 1 showed that the median EFS in patients with luminal B BC was 9 months, with triple-negative BC (TNBC) 8 months. 6-month EFS in luminal B subtype was 87.5%, in TNBC 79.4%, p=0.37985. 1-year EFS was 1.721.7% regardless of the biological subtype. The median OS in luminal B BC was 25 months, in TNBC 26 months. 1-year OS in luminal B BC 100%, in TNBC 93.9%, p=0.138. 2-year OS in luminal B BC 54.2%, in TNBC 55.9%, p=0.697. 3-year survival in luminal B BC 37.5%, in TNBC 41.2%, p=0.639. An analysis of OS and EFS in group 2 showed that the median EFS was not reached for all biological subtypes. 3-year survival in the group was 100% regardless of the biological subtype. The median OS was not reached for all biological subtypes. 3-year OS in the group was 100%. An analysis of the hormonal profile in the treatment dynamics showed decreased levels of estradiol in all groups of patients (by 1.6 times). In group 1, progesterone was decreased by 2.1 times, testosterone by 2.4 times and LH by 2.1 times in all BC subtypes (p0.05). Patients of group 2 showed 2 times reduced cortisol and 3 times reduced prolactin in all BC subtypes, while LH levels were elevated by 1.6 times in luminal A and B BC. Conclusion. Aggressive course was observed similarly in triple-negative cancer as well as in luminal cancer with primary hormone resistance. Studying of pituitary and sex hormones and cortisol have a great clinical significance in patients with all biological subtypes of BC. This should be taken into account when predicting the course of the disease and developing further treatment options.
format	article
author	Natalia I. Samaneva Liubov I. Vladimirova Irina V. Kolyadina Elena M. Frantsiyants Anna E. Storozhakova Valeriya A. Bandovkina Elena A. Kalabanova Sergei N. Kabanov Iana V. Svetitskaya Anna V. Tishina Mariia O. Ezhova
author_facet	Natalia I. Samaneva Liubov I. Vladimirova Irina V. Kolyadina Elena M. Frantsiyants Anna E. Storozhakova Valeriya A. Bandovkina Elena A. Kalabanova Sergei N. Kabanov Iana V. Svetitskaya Anna V. Tishina Mariia O. Ezhova
author_sort	Natalia I. Samaneva
title	Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
title_short	Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
title_full	Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
title_fullStr	Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
title_full_unstemmed	Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
title_sort	prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable her2-negative breast cancer
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/a9fdf814b2364cbe9492945661d48d9f
work_keys_str_mv	AT nataliaisamaneva prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT liubovivladimirova prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT irinavkolyadina prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT elenamfrantsiyants prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT annaestorozhakova prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT valeriyaabandovkina prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT elenaakalabanova prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT sergeinkabanov prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT ianavsvetitskaya prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT annavtishina prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer AT mariiaoezhova prognosticroleofclinicalandbiologicalfactorsandparametersofhormonalprofileinpatientswithprimaryinoperableher2negativebreastcancer
_version_	1718406464352026624

Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer

Ejemplares similares